This page shows what was measured, who it was measured in, and what that does not settle.
What Mycophenolate Mofetil does in the body
Organ rejection
From the FDA-approved label: Mycophenolate mofetil has been demonstrated in experimental animal models to prolong the survival of allogeneic transplants (kidney, heart, liver, intestine, limb, small bowel, pancreatic islets, and bone marrow). Mycophenolate mofetil has also been shown to reverse ongoing acute rejection in the canine renal and rat cardiac allograft models. Mycophenolate mofetil also inhibited proliferative arteriopathy in experimental models of aortic and cardiac allografts in rats, as well as in primate cardiac xenografts. Mycophenolate mofetil was used alone or in combination with other immunosuppressive agents in these studies.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
Its recorded molecular formula is C23H31NO7, weighing 433.50.
US prescribing information · ce06afcb-4e6c-4b78-8bad-9909c8fffa52 · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 105 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Overall survival
✗ The study did not show it
Who was studied
NCT02416388
How many people
3100
Study design
Phase 2/Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Measurement of inflammatory cytokines (interleukin (IL) 1 beta, IL-1RA, IL-6, IL-18, tumor necrosis factor (TNF) alpha, CXCL9 and CXCL10) on serum of patients
✗ The study did not show it
Who was studied
NCT05670301
How many people
2500
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2.
✗ The study did not show it
Who was studied
NCT01950819
How many people
2037
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Subproject A: Disease safety (flare) in ARD patients immunized with RZV in comparison to non-vaccinated ARD patients (placebo group)
✗ The study did not show it
Who was studied
NCT05879419
How many people
2005
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
GFR calculated from the serum creatinine with the Cockcroft-Gault formula at 12 months posttransplantation
✗ The study did not show it
Who was studied
NCT00231764
How many people
1760
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Efficacy failure rate
✗ The study did not show it
Who was studied
NCT00717470
How many people
1252
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Mycophenolate mofetil for oral suspension is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1) ], heart [see Clinical Studies (14.2) ] or liver transplants [see Clinical Studies (14.3) ], in combination with other immunosuppressants.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness have been established in pediatric patients 3 months and older for the prophylaxis of organ rejection of allogenic kidney, heart or liver transplants.”
US prescribing information · ce06afcb-4e6c-4b78-8bad-9909c8fffa52 · read 2026-08-30
On older people, the label states: “Clinical studies of mycophenolate mofetil did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.”
US prescribing information · ce06afcb-4e6c-4b78-8bad-9909c8fffa52 · read 2026-08-30
On people who are pregnant, the label states: “Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment.”
US prescribing information · ce06afcb-4e6c-4b78-8bad-9909c8fffa52 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of mycophenolate in human milk, or the effects on milk production.”
US prescribing information · ce06afcb-4e6c-4b78-8bad-9909c8fffa52 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S6.
No source is stored against this line.
What is in the pack
Sold as capsule, tablet, injectable, for suspension, given by the oral, injection, intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
83 products list this as an active ingredient in the United States drug directory. 83 of them contain it and nothing else.
FDA National Drug Code directory · 14593-876 · read 2026-08-29
They are sold as capsule, injection, injection, powder, lyophilized, for solution, powder, powder, for suspension and suspension, taken intravenous and oral.
FDA National Drug Code directory · 14593-876 · read 2026-08-29
The regulator's established pharmacologic class for it is antimetabolite immunosuppressant [epc].
FDA National Drug Code directory · 14593-876 · read 2026-08-29
48 published labels name it as an active ingredient. 48 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · ce06afcb-4e6c-4b78-8bad-9909c8fffa52 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · ce06afcb-4e6c-4b78-8bad-9909c8fffa52 · read 2026-08-29
Mycophenolate mofetil is oral at 3 DOSAGE FORMS AND STRENGTHS Mycophenolate mofetil for tablets are available in the following dosage form and strength: Tablets 500 mg mycophenolate mofetil, pinkish brown colored, capsule shaped, film coated tablet wit…, recorded as fda label in effect 2023-10-01 in the United States.
US prescribing information · ce06afcb-4e6c-4b78-8bad-9909c8fffa52 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Mycophenolate Mofetil studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Mycophenolate Mofetil are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
48 documents were read for this substance.
RNAWiki source record
47 of them state the same bioavailability, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
9242ECW6R0
RxNorm concept
200060
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
Withdrawn in United States, 2019, for "Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product" (openFDA drug enforcement Class I recall)
What the approval register records
56 approved applications cover products containing this substance. The earliest was NDA050722, approved 19950503 to ROCHE PALO.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (9)
Q2
On the Mycophenolate Mofetil label: indicated for what?
"1 INDICATIONS & USAGE Mycophenolate mofetil (MMF) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies ( 14.1 )], heart [see Clinical Studies ( 14.2 )] or liver transplants [see Clinical Studies ( 14.3 )] , in…": indications and usage on Mycophenolate Mofetil's label. DailyMed label · fbbe6521-0e21-5372-e053-6394a90ae5e4 · 2026-08-25
Q3
738 registered trials of Mycophenolate Mofetil — at which phases?
Registered studies posting no result
440 of 738
738 registered studies of Mycophenolate Mofetil: 359 phase2, 123 phase1, 123 phase4, 110 phase3, 53 na, 28 na or unstated, 9 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Poor accrual and difficulty with multicenter logistics"; 126 of 738 registered studies
Show the evidence
Trial
NCT00041288
terminated; "Poor accrual and difficulty with multicenter logistics"
NCT00053014
terminated; "Poor accrual"
NCT00057954
terminated; "Slow accrual"
NCT00085449
withdrawn; "Funding cut, no patients enrolled"
NCT00089141
terminated; "Low probability of positive outcome"
NCT00119366
terminated; "Funding ended before target accrual was reached; participants are no longer being examined or receiving intervention."
14 further recorded trials
NCT00133172
terminated; "Varience of supply chain from that required by protocol"
NCT00151632
terminated; "insufficient enrollment"
NCT00166712
terminated; "Study stopped due to lack of efficacy \& funding."
NCT00203281
withdrawn; "funding withdrawn"
NCT00217152
terminated; "Roche decided to prematurely terminate study."
NCT00230035
withdrawn; "Recommended by DSMB due to lack of accrual"
NCT00243009
terminated; "Due to a lack of a referal base, study was terminated."
NCT00255684
terminated; "low accrual"
NCT00282412
terminated; "No participant enrolled for three years. No plan to continue study."
NCT00290628
terminated; "Replaced with another study"
NCT00303719
terminated; "IRB Study Closure"
NCT00311311
terminated; "See termination reason in detailed description."
NCT00318474
terminated; "DSMB recommended stopping the trial because of lack of effect."
NCT00354172
terminated; "Competing study was started."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Mycophenolate Mofetil used Mycophenolate Mofetil 250mg — over how long?
studies of Mycophenolate Mofetil used the recorded amount. ClinicalTrials.gov · 2026-09-01
4 recorded entries; human; also "Mycophenolate Mofetil 250mg", "Mycophenolate Mofetil Capsule 250 mg", "Mycophenolate Mofetil 500mg"
Show the evidence
human
NCT00899847
Mycophenolate Mofetil 250mg
NCT01080417
Mycophenolate Mofetil Capsule 250 mg
NCT01842269
Mycophenolate Mofetil 500mg
NCT06068179
Mycophenolate Mofetil, Oral, 250 Mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Which running trial of Mycophenolate Mofetil could settle lifespan?
NCT06789315 measures To compare the efficacy of MMF versus steroid therapy in improving short-term (28 day) survival outcomes in patients with alcoholic hepatitis, reading out 2026-01-31.
28 open trials; n 60; "Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis"
Show the evidence
Trial
NCT06789315
"Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis"; n 60; "To compare the efficacy of MMF versus steroid therapy in improving short-term (28 day) survival outcomes in patients with alcoholic hepatitis"; 2026-01-31
NCT04547049
"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies"; n 232; "Overall survival (OS)"; 2026-04-01
NCT05622318
"De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis"; n 56; "The number of subjects who experience GVHD-free survival."; 2026-09
NCT04187105
"BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)"; n 27; "Rate of 1 year Graft-Versus-Host Disease (GVHD) free, relapse free survival (GRFS) survival"; 2026-12
NCT04904588
"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide"; n 300; "Overall Survival"; 2026-12
NCT04644016
"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders"; n 31; "Treatment related mortality at 1 year after myeloablative cord transplant"; 2026-12-20
14 further recorded trials
NCT06001385
"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis"; n 313; "Infection Free Survival"; 2026-12-30
NCT05736419
"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)"; n 24; "Number of participants with treatment related mortality/TRM or primary graft failure"; 2027-02-09
NCT02081755
"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer"; n 336; "Disease free survival (DFS) defined as the time from randomization to the time of tumor recurrence or death, whichever occurs first."; 2027-03
NCT05303727
"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma"; n 64; "overall survival(OS) at 3 year"; 2027-08
NCT04888741
"Methods of T Cell Depletion Trial (MoTD)"; n 400; "GVHD-free, relapse-free survival"; 2027-08-23
NCT02558452
"European Transplant Registry of Senior Renal Transplant Recipients on Advagraf"; n 1000; "Patient survival"; 2028-01
NCT02782546
"Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation"; n 60; "Kaplan-Meier Estimate of Leukemia-free Survival Rate (LFS)"; 2028-02-13
NCT05088356
"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft"; n 66; "Determine the GVHD-free relapse-free survival (GRFS) post-HCT ( Arm-A)"; 2028-05
NCT00882895
"Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma"; n 18; "Determine the event free survival"; 2028-06-01
NCT07634536
"Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant"; n 30; "Non-Relapse Mortality (NRM)"; 2028-08
NCT02861417
"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant"; n 204; "Non-relapse mortality rate"; 2028-08-31
NCT06680661
"ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis"; n 20; "Severe aGVHD free survival"; 2028-10-31
NCT07359859
"A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant"; n 40; "assess cGVHD-free survival"; 2029-01
NCT07566377
"Cord Blood Transplantation in Children and Young Adults With Blood Cancer"; n 71; "Disease-free Survival (DFS)"; 2030-04-28
Q7
Which 177 trials of Mycophenolate Mofetil posted no result?
Posted no result
177 of 177 completed trials
Registrations
NCT00006350, NCT00005935, NCT00003196, NCT00003572, NCT00008151 and NCT00149929, and 171 more
Completion dates
oldest 2001-11; newest 2024-08-19
Show the evidence
Trial
NCT00006350
2001-11
NCT00005935
2002-03
NCT00003196
2002-04
NCT00003572
2002-04
NCT00008151
2002-07
NCT00149929
2003-04
14 further recorded trials
NCT00006233
2003-12
NCT00149864
2003-12
NCT00693524
2004-03
NCT00001764
2004-06
NCT00004567
2004-06
NCT00027547
2004-07
NCT00693381
2004-08
NCT00027820
2004-09-05
NCT00187915
2004-12
NCT00261820
2005-01
NCT00005941
2005-06
NCT00812123
2005-07
NCT00893542
2005-11
NCT00893919
2005-11
Q8
At the median, Mycophenolate Mofetil's trials enrolled 45.5 people — anything larger?
Median enrolment
45.5
Largest enrolment
2000
Registered trials counted
728
Q9
What do 9912 spontaneous reports say about Mycophenolate Mofetil — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Mycophenolate Mofetil appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 9912 reaction mentions were counted: transplant rejection 1766; cytomegalovirus infection 1746; leukopenia 983; renal impairment 873. FAERS via Open Targets · CHEMBL1200955 · 2026-06-24
Show the evidence
transplant rejection
1766
cytomegalovirus infection
1746
leukopenia
983
renal impairment
873
covid-19
852
post transplant lymphoproliferative disorder
816
4 more recorded rows
treatment failure
797
kidney transplant rejection
726
polyomavirus-associated nephropathy
714
transplant dysfunction
639
recorded 2026-06-24 · last checked 2026-09-04
Q10
Which 10 reactions does Mycophenolate Mofetil's label not list?
2 label terms; 10 reported and unlisted; fbbe6521-0e21-5372-e053-6394a90ae5e4
Show the evidence
covid-19
count not stated
cytomegalovirus infection
count not stated
kidney transplant rejection
count not stated
leukopenia
count not stated
polyomavirus-associated nephropathy
count not stated
post transplant lymphoproliferative disorder
count not stated
4 more recorded rows
renal impairment
count not stated
transplant dysfunction
count not stated
transplant rejection
count not stated
treatment failure
count not stated
recorded 2026-06-24 · last checked 2026-09-04
Where it is registered
Where it’s registered
Withdrawn in United States, 2019, for "Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product" (openFDA drug enforcement Class I recall)
ChEMBL 37 — CC BY-SA 3.0 Unported · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work · openFDA enforcement — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 7 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.